Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Rathbun “seconded” To SAFE-BioPharma

Executive Summary

George Rathbun will continue as Pfizer's global research development informatics director as he assumes the additional position of SAFE-BioPharma Association chief technology officer. "Pfizer has seconded Rathbun to SAFE-BioPharma," the industry-sponsored organization says in a Nov. 17 release. Rathbun, who will take over the new position immediately, will oversee and manage all aspects of technology for the organization, which is responsible for developing and managing secure digital signature standards (1"The Pink Sheet" July 11, 2005, p. 25)...

You may also be interested in...



Rx Industry E-Signature Standard Will Be Used In NCI Clinical Trials In 2006

A digital signature standard developed by the pharmaceutical industry will be ready for use in National Cancer Institute studies by 2006

India To Scrap Intellectual Property Appellate Board: Should Pharma Worry?

Legal experts tell the Pink Sheet why India’s plans to abolish the Intellectual Property Appellate Board and shift its powers to courts may be problematic for stakeholders, including those pursuing infringement charges. The transition could mean a significant burden on courts both in terms of capability and capacity, and IPR cases will now conflate into all other pending commercial matters, some experts said, though others cheered the proposed change.

QUOTED. 5 March 2021. Dedi Gilad.

Tyto Care’s remote monitoring and telehealth platform has seen rising demand since the start of the pandemic and the company continues to expand. This week, it announced it raised $50m in a series D financing round. See what Dedi Gilad, CEO of Tyto Care, said about it here.

Topics

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel